中国医药
中國醫藥
중국의약
CHINA MEDICINE
2011年
10期
1195-1197
,共3页
肝炎,乙型,慢性%HLA-DRB1抗原%聚乙二醇干扰素α-2a%聚合酶链反应%序列特异性引物
肝炎,乙型,慢性%HLA-DRB1抗原%聚乙二醇榦擾素α-2a%聚閤酶鏈反應%序列特異性引物
간염,을형,만성%HLA-DRB1항원%취을이순간우소α-2a%취합매련반응%서렬특이성인물
Hepatitis B,chronic%HLA-DRB1 antigen%PEG-interferon α-2a%Polymerase chain reaction%Sequence specific primes
目的 探讨青岛地区汉族慢性乙型病毒性肝炎患者聚乙二醇干扰素治疗疗效与人类白细胞抗原( HLA) -DRB1等位基因的关系。方法 以接受聚乙二醇干扰素α-2a正规治疗48周的青岛地区汉族慢性乙型肝炎患者40例作为研究对象，应用聚合酶链反应-序列特异性引物技术对患者的HLA-Ⅱ类抗原的DRB1*04、*07进行等位基因检测，应用SC2000统计软件对结果进行分析。结果 40例慢性乙型肝炎患者接受聚乙二醇干扰素α-2a治疗48周后，完全应答者19例(47.5％)，部分应答者10例(25.0％)，无应答者11例(27.5％)。无应答者11例中，HLA-DRB1*04携带者4例，HLA-DRB1* 07携带者7例；部分、完全应答者29例中，HLA-DRB1* 04携带者1例；HLA-DRB1*07携带者6例，无应答者HLA-DRB1*04和*07携带率均明显高于部分、完全应答者（前者P＜0.05,OR= 16.0；后者P＜0.05，OR =6.7）。结论 青岛地区汉族人群中慢性乙型肝炎聚乙二醇干扰素α-2a治疗无应答与HLA-DRB1*04、*07呈正相关。
目的 探討青島地區漢族慢性乙型病毒性肝炎患者聚乙二醇榦擾素治療療效與人類白細胞抗原( HLA) -DRB1等位基因的關繫。方法 以接受聚乙二醇榦擾素α-2a正規治療48週的青島地區漢族慢性乙型肝炎患者40例作為研究對象，應用聚閤酶鏈反應-序列特異性引物技術對患者的HLA-Ⅱ類抗原的DRB1*04、*07進行等位基因檢測，應用SC2000統計軟件對結果進行分析。結果 40例慢性乙型肝炎患者接受聚乙二醇榦擾素α-2a治療48週後，完全應答者19例(47.5％)，部分應答者10例(25.0％)，無應答者11例(27.5％)。無應答者11例中，HLA-DRB1*04攜帶者4例，HLA-DRB1* 07攜帶者7例；部分、完全應答者29例中，HLA-DRB1* 04攜帶者1例；HLA-DRB1*07攜帶者6例，無應答者HLA-DRB1*04和*07攜帶率均明顯高于部分、完全應答者（前者P＜0.05,OR= 16.0；後者P＜0.05，OR =6.7）。結論 青島地區漢族人群中慢性乙型肝炎聚乙二醇榦擾素α-2a治療無應答與HLA-DRB1*04、*07呈正相關。
목적 탐토청도지구한족만성을형병독성간염환자취을이순간우소치료료효여인류백세포항원( HLA) -DRB1등위기인적관계。방법 이접수취을이순간우소α-2a정규치료48주적청도지구한족만성을형간염환자40례작위연구대상，응용취합매련반응-서렬특이성인물기술대환자적HLA-Ⅱ류항원적DRB1*04、*07진행등위기인검측，응용SC2000통계연건대결과진행분석。결과 40례만성을형간염환자접수취을이순간우소α-2a치료48주후，완전응답자19례(47.5％)，부분응답자10례(25.0％)，무응답자11례(27.5％)。무응답자11례중，HLA-DRB1*04휴대자4례，HLA-DRB1* 07휴대자7례；부분、완전응답자29례중，HLA-DRB1* 04휴대자1례；HLA-DRB1*07휴대자6례，무응답자HLA-DRB1*04화*07휴대솔균명현고우부분、완전응답자（전자P＜0.05,OR= 16.0；후자P＜0.05，OR =6.7）。결론 청도지구한족인군중만성을형간염취을이순간우소α-2a치료무응답여HLA-DRB1*04、*07정정상관。
Objective To study the relationship between efficacy of PEG-interferon α-2a for forty-eight weeks and some HLA alleles ( HLA-DRB1 ) in the patients with chronic viral hepatitis B from Qingdao of the Hannationality, and provide immuno-genetic knowledge for the prevention and cure of hepatitis B virus infection.Methods Forty patients with chronic viral hepatitis B in a Qingdao population of the Han nationality were subjected to a standard course of treatment with PEG-interferon α-2a for 48 weeks. HLA-DRB1 * 04, * 07 were detected by using the polymerase chain reaction-sequence specific primer (PCR-SSP) technique. The data were analyzed by SC2000 software. Results After forty patients with chronic viral hepatitis B were subjected to a course of treatment with PEG-interferon α-2a for 48 weeks, there were nineteen patients in the complete-responders, ten patients in the partial-responders and eleven patients in non-responders. The patients of HLA-DRB1 * 04 in eleven non-responders were four and in twenty-nine partial-or complete-responders was one. The frequency of HLA-DRB1 * 04 in non-responders was higher than that in the partial-or complete-responders (P ＜0.05 ,OR = 16.0). The patients of HLADRB1 * 07 in eleven non-responders were seven and in twenty-nine partial-or complete-responders were six. The frequency of HLA-DRB1 * 07 in non-responders was higher than that in the partial-or complete-responders ( P ＜ 0.05,OR =6.7 ). Conclusions In a Qingdao population of the Han nationality, no response of PEG-interferon α-2a therapy in the patients with chronic viral hepatitis B was correlated positively with HLA-DRB1 * 04, * 07.
